Paradigm Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Paradigm Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,400	Closed	-$39K	–	415
2017 Q2	$39K	Sell	1,400 -1,500	-52%	-$44.7K	0.01%	537
2017 Q1	$99.7K	Sell	2,900 -15,600	-84%	-$551K	0.02%	528
2016 Q4	$534K	Sell	18,500 -500	-3%	-$13.2K	0.1%	204
2016 Q3	$604K	Buy	19,000 +300	+2%	+$10.2K	0.11%	226
2016 Q2	$607K	Sell	18,700 -8,400	-31%	-$281K	0.11%	196
2016 Q1	$758K	Hold	27,100	–	–	0.14%	131
2015 Q4	$966K	Sell	27,100 -44,200	-62%	-$1.56M	0.17%	115
2015 Q3	$2.36M	Buy	71,300 +37,100	+108%	+$1.54M	0.31%	101
2015 Q2	$1.43M	Hold	34,200	–	–	0.16%	166
2015 Q1	$1.11M	Buy	+34,200	New	+$1.18M	0.12%	187

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Paradigm Asset Management's ACAD Position: Q3 2017 in Review

Paradigm Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2017, closing a stake of 1,400 shares — an estimated $39K sold.

Paradigm Asset Management first reported a position in ACAD in Q1 2015 and held it in 10 quarters. The position peaked at $2.36M in Q3 2015. 212 funds tracked by Wall St. Rank hold ACAD as of Q3 2017.

Paradigm Asset Management reported no remaining Acadia Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Paradigm Asset Management sold 1,400 Acadia Pharmaceuticals shares in Q3 2017, an estimated $39K.
Paradigm Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 10 quarters.
Paradigm Asset Management's Acadia Pharmaceuticals position peaked at $2.36M in Q3 2015.
212 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.